Evidence map›Paper›PMID 41884834›Full record

ArticleFrontiers in immunology2026

The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.

Wenhao Li, Jiewen Deng, Hao Zhang, Menghan Zhang, Chuanxu Kang, Zicheng Yu, Yunshen Gu, Xiaobo He, Yanfeng Wu

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenhao Li *National Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Jiewen Deng *Department of Cardiovascular Diseases, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hao Zhang *National Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Menghan Zhang *National Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Chuanxu KangNational Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Zicheng YuNational Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Yunshen GuNational Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Xiaobo HeNational Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
Yanfeng WuNational Key Laboratory of Immunity and Inflammation & Institute of Immunology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) continues to pose a significant clinical challenge due to its high mortality rate and limited treatment efficacy. The role of disulfidptosis, a recently discovered mode of regulatory cell death, in pancreatic cancer progression and tumor immunity remains poorly understood. Methods: We developed and validated a disulfidptosis-related prognostic signature based on 13 pivotal genes. Integrated multi-omics approaches, incorporating bulk and single-cell transcriptomics, spatial transcriptomics, and functional assays, were employed to investigate the association between disulfidptosis and key biological processes. Results: The prognostic signature effectively stratified PDAC patients into distinct risk categories with markedly different clinical outcomes and exhibited consistent predictive accuracy across multiple independent cohorts. It informed personalized treatment strategies, revealing differential sensitivity to therapeutic agents including dasatinib and UMI-77. Multi-omics analyses revealed that disulfidptosis is closely associated with redox homeostasis, cytoskeletal organization, and immune evasion. The high-risk subgroup displayed an immunosuppressive tumor microenvironment, characterized by diminished CD8 Conclusion: Our study develops a novel prognostic framework for patient stratification based on disulfidptosis-related genes in PDAC. Integrated multi-omics analyses reveal a strong association between disulfidptosis and an immunosuppressive tumor microenvironment, positioning it as a candidate metabolic vulnerability that warrants further functional investigation. These findings offer correlative insights into the involvement of disulfidptosis in immune regulation and suggest that further exploration of this pathway may inform future immunotherapeutic strategies.

Indexed as

Carcinoma, Pancreatic DuctalDisulfidptosisPancreatic NeoplasmsTumor MicroenvironmentBiomarkers, TumorDisease ProgressionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, Tumordisulfidptosisimmune infiltrationpancreatic cancerprognosistumor microenvironmentUBASH3B

Identifiers

PMID41884834
PMCPMC13008902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.